Literature DB >> 22184285

Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma.

Kieron Dunleavy1, Wyndham H Wilson.   

Abstract

Gene expression profiling has been used to divide diffuse large B-cell lymphoma into distinct molecular subtypes with different outcomes following immunochemotherapy. Recently, researchers have shown much interest in investigating the role of biomarkers, such as BCL2, in predicting outcome in diffuse large B-cell lymphoma, particularly in the context of these molecular subtypes. ©2011 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22184285      PMCID： PMC3531963          DOI： 10.1158/1078-0432.CCR-11-2372

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Authors:  Javeed Iqbal; Paul N Meyer; Lynette M Smith; Nathalie A Johnson; Julie M Vose; Timothy C Greiner; Joseph M Connors; Louis M Staudt; Lisa Rimsza; Elaine Jaffe; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Wing C Chan
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

2.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

Authors:  R D Gascoyne; S A Adomat; S Krajewski; M Krajewska; D E Horsman; A W Tolcher; S E O'Reilly; P Hoskins; A J Coldman; J C Reed; J M Connors
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

3.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Authors:  Wyndham H Wilson; Owen A O'Connor; Myron S Czuczman; Ann S LaCasce; John F Gerecitano; John P Leonard; Anil Tulpule; Kieron Dunleavy; Hao Xiong; Yi-Lin Chiu; Yue Cui; Todd Busman; Steven W Elmore; Saul H Rosenberg; Andrew P Krivoshik; Sari H Enschede; Rod A Humerickhouse
Journal:  Lancet Oncol       Date:  2010-11-18       Impact factor: 41.316

4.  Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

Authors:  Ali R Jazirehi; Sara Huerta-Yepez; Genhong Cheng; Benjamin Bonavida
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

Review 5.  Double-hit B-cell lymphomas.

Authors:  Sietse M Aukema; Reiner Siebert; Ed Schuuring; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Evert-Jan Boerma; Philip M Kluin
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

6.  Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.

Authors:  Wyndham H Wilson; Michael L Grossbard; Stefania Pittaluga; Diane Cole; Deborah Pearson; Nicole Drbohlav; Seth M Steinberg; Richard F Little; John Janik; Martin Gutierrez; Mark Raffeld; Louis Staudt; Bruce D Cheson; Dan L Longo; Nancy Harris; Elaine S Jaffe; Bruce A Chabner; Robert Wittes; Frank Balis
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

7.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Authors:  Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

8.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining.

Authors:  Y Tsujimoto; J Gorham; J Cossman; E Jaffe; C M Croce
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

9.  Stromal gene signatures in large-B-cell lymphomas.

Authors:  G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307
View more
  5 in total

1.  Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.

Authors:  Kieron Dunleavy; Cliona Grant; Wyndham H Wilson
Journal:  Ther Adv Hematol       Date:  2013-02

Review 2.  Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Oncology (Williston Park)       Date:  2014-04       Impact factor: 2.990

3.  P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.

Authors:  Gabriel G Vega; Alejandro Avilés-Salas; J Ramón Chalapud; Melisa Martinez-Paniagua; Rosana Pelayo; Héctor Mayani; Rogelio Hernandez-Pando; Otoniel Martinez-Maza; Sara Huerta-Yepez; Benjamin Bonavida; Mario I Vega
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

4.  Novel prognostic genes of diffuse large B-cell lymphoma revealed by survival analysis of gene expression data.

Authors:  Chenglong Li; Biao Zhu; Jiao Chen; Xiaobing Huang
Journal:  Onco Targets Ther       Date:  2015-11-18       Impact factor: 4.147

5.  A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.

Authors:  E Horvilleur; T Sbarrato; K Hill; R V Spriggs; M Screen; P J Goodrem; K Sawicka; L C Chaplin; C Touriol; G Packham; K N Potter; S Dirnhofer; A Tzankov; M J S Dyer; M Bushell; M MacFarlane; A E Willis
Journal:  Leukemia       Date:  2013-10-18       Impact factor: 11.528
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.